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Abstract
Aim: We assess the cost-benefit implications of C-reactive protein (CRP) testing in reducing antibiotic prescription
for acute respiratory infection in Viet Nam by comparing the incremental costs of CRP testing with the economic
costs of antimicrobial resistance averted due to lower antibiotic prescribing.
Findings: Patients in the CRP group and the controls incurred similar costs in managing their illness, excluding the
costs of the quantitative CRP tests, provided free of charge in the trial context. Assuming a unit cost of $1 per test,
the incremental cost of CRP testing was $0.93 per patient. Based on a previous modelling analysis, the 20
percentage point reduction in prescribing observed in the trial implies a societal benefit of $0.82 per patient. With
the low levels of adherence to the test results observed in the trial, CRP testing would not be cost-beneficial. The
sensitivity analyses showed, however, that with higher adherence to test results their use would be cost-beneficial.
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Background
It is estimated that 80–90% of antibiotic prescription oc-
curs in primary care, of which half are for acute respira-
tory infection (ARI) [1, 2]. Antibiotic use is unrestricted
in Viet Nam, and prescription and sales of antibiotics for
ARI is very common in- and outside primary health care
settings [3] despite a predominantly viral etiology [4].
Approximately 70% of primary care patients in Viet
Nam are prescribed antibiotics, and ARI is the reason
for 51% of these [5]. Treatment decisions are at best
based on clinical examination, which in both low and
high income settings is of poor accuracy in identifying
when antibiotics are required, and is often inadequately
performed [3, 6, 7].
The interaction between antimicrobial consumption
and antimicrobial resistance (AMR) is complex, however,
it is widely accepted that safe reductions in consumption
will have the desirable effect of mitigating the burden of
AMR [8]. A recent modelling study estimated the eco-
nomic costs of AMR per antibiotic consumed, equating
with the societal gains for every course of antibiotics
averted [9]. For example, in the Thai context, the con-
sumption of a full course of beta-lactams was associated
with an economic cost of $10.8 due to AMR.
Several biomarker tests have been evaluated for this
purpose in the context of ARIs in primary care, and
C-reactive protein (CRP) has been shown to have high
discriminatory power in distinguishing between viral and
bacterial infections, in the range of 85–95% sensitivity
and 50–75% specificity [10–12]. A meta-analysis of clin-
ical trials concluded that CRP tests can safely reduce
antibiotic prescribing [13].
Point-of-care (PoC) CRP tests are commercially avail-
able and can be performed in primary care using
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capillary blood samples, with results available within mi-
nutes [14, 15]. This approach is already taken in a num-
ber of high income countries such as Norway and
Sweden [16] and is recommended by Public Health Eng-
land and the National Institute for Health and Clinical
Excellence (NICE) [17]. In low and middle income coun-
tries (LMICs), and in Asia in particular, no such tests are
in routine use and antibiotic dispensing is often unregu-
lated or regulation is poorly enforced and resistance
levels are high and increasing [18–21]. Despite the ur-
gent need to improve antibiotic targeting in these set-
tings, the necessary evidence on the cost-effectiveness of
biomarker testing is scarce.
A randomised control trial in Viet Nam compared
CRP PoC testing with routine care in the management
of ARIs in primary care, finding significant reductions in
antibiotic prescription without compromising patient re-
covery and satisfaction [22]. To determine whether the
incremental cost of introducing CRP tests is economic-
ally justifiable, this needs to be compared with the soci-
etal costs of AMR the tests could avert. In this short
report, we use primary cost data collected in the trial
and the output of the modelling analysis of the eco-
nomic costs of AMR per antibiotic consumed to per-
form a cost-benefit analysis of CRP testing in primary
care in the Vietnamese setting.
Methods
This cost-benefit analysis of CRP testing takes a societal
perspective. Primary cost data were collected in a clinical
trial on CRP testing in primary care as described in the
Additional file 1: Tables S1 and S2, comparing the costs
of managing ARI in the intervention group as compared
with controls. The CRP readers and reagents used in the
study were donated by the manufacturer, with a pur-
chase cost per kit of approximately $3 and for a single
reader $1000. If implemented at scale, CRP testing could
be carried out using simple lateral flow devices that can
be used by relatively untrained personnel. Such tests
have been shown to be accurate and available at under
$0.5 [15, 23]. By way of comparison World Health Or-
ganisation (WHO) pre-qualified lateral flow malaria
rapid diagnostic tests (RDTs) are available at under $0.3.
We conservatively assume here a unit cost of $1 per test,
allowing for added costs for import tariffs, shipment,
training, and other peripheral expenses.
The trial results showed no difference in clinical out-
comes between the study arms, therefore the benefits
considered here relate only to the societal costs of AMR
averted due to lower prescribing. Estimates for the eco-
nomic cost of AMR per antibiotic prescribed are taken
from a modelling analysis where these were calculated in
the US and Thai contexts [9]. The Thai costs were ad-
justed by a factor of 0.38 using the ratio of 2017 GDP
per capita (PPP) in Viet Nam to that of Thailand (0.38 *
$10.8 = $4.1). We thus assign an economic cost of AMR
of $4.1 per full course of broad spectrum beta-lactams,
the drug class most often prescribed in the study. The
net benefit of CRP testing is calculated as
NMBcrp ¼ ΔpAB  cAMR− ΔDC þ Ctð Þ ð1Þ
where NMB is the net monetary benefit of CRP test-
ing, ΔpAB is the percentage difference in prescribing be-
tween patients in the CRP group and controls; cAMR is
the cost of AMR per antibiotic consumed; ΔDC is the
difference in direct medical care as observed in the trial;
and Ct is the direct cost of the CRP tests. A positive net
monetary benefit indicates that CRP testing is
cost-beneficial. All costs are assumed to be incurred at
the time patients are presenting at the health centre,
therefore no discounting is applied.
A three-way sensitivity analysis was carried out for key
drivers of the net-monetary benefit: 1) the cost of the
CRP tests, ranging from $0.5 to $3; 2) adherence to test
results indicating low CRP (i.e. not prescribing antibi-
otics to patients with low CRP concentrations, which oc-
curred in 64% of cases in the trial context) ranging from
50 to 100%; and 3) the economic cost of AMR, ranging
from $0 to $14 per course of antibiotics, using the upper
bound of the range of costs of AMR per full course of
broad spectrum beta-lactam as described in Shrestha et
al. (2018) [9], adjusted by the per-capita GDP ratios of
Viet Nam and Thailand.
The data were analyzed and the cost-benefit analysis
were run in R version 3.2.2 (R Foundation for Statistical
Computing, Vienna, Austria) and using the R Color
Brewer package.
Results
Trial primary outcome and costs
There was a 20 percentage point risk difference in pre-
scribing on first attendance between patients in the
intervention group (43%) and the controls (63%). As de-
tailed in the Additional file 1: Table S1, the direct costs
of management of ARI in the trial were $1.24 and $1.31
in the CRP group and the controls, respectively, with no
significant difference (p = 0.28). The slight reduction in
costs were explained by the lower rate of antibiotic pre-
scribing in the intervention group.
Modelled cost-benefit outcomes
With the additional assumed cost per CRP test of $1,
the incremental cost per patient with the use of the test
was $0.93. With a cost of AMR per full course of antibi-
otics of $4.1, the use of the test results in a negative
net-monetary benefit, implying that with a 20 percentage
point reduction in prescribing, the use of the test was
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not cost-beneficial. Figure 1 presents the sensitivity ana-
lysis for the net-benefit of the tests to their unit cost, the
adherence to negative test results, and to the economic
cost of AMR. This suggests that without consideration
of the costs of AMR, the use of the tests is not
cost-beneficial even with a low cost test and with high
adherence to their results. With the inclusion of a cost
of AMR of $4.1 per course of antibiotics, the test has a
positive net-benefit if adherence exceeds 70% and the
cost of the test is <=$0.5, or with adherence at 80% and
a unit cost per test of $1. A higher cost of AMR of $14.1
per full course of antibiotics would imply a positive
NMB so long as adherence exceeded 60%, even if the
cost per test was as high as $3.
Discussion
The trial demonstrated that CRP testing could safely re-
duce antibiotic prescription in primary health care set-
tings. The primary cost data indicate that other than the
cost of the test, there were no added direct medical costs
and potential cost savings associated with the inter-
vention. Assuming a unit cost per test of $1, the in-
cremental cost per patient would be $0.93. With an
estimated societal cost of AMR of $4.1 per course of
a broad spectrum beta-lactam, the use of the tests
would not appear to be cost-beneficial due to the
limited adherence to their results. The sensitivity ana-
lysis, however, indicated that the tests could be
cost-beneficial if healthcare workers refrained from
prescribing to patients with low CRP at higher rates
than observed in the trial.
Implications of the study
The Wellcome Trust AMR Review estimated that by
2050 global economic losses due to AMR could accumu-
late to $124 trillion [24]. Who should be funding inter-
ventions to mitigate the spread of AMR is a challenging
question. Patients or even policy makers in LMICs
might not view this as a priority over interventions with
more tangible short term benefits; this would imply lim-
ited and sub-optimal uptake from the global community
perspective in its efforts to tackle AMR. The AMR Re-
view appropriately highlighted the need for a global
funding mechanism (‘Diagnostic Market Stimulus pots’),
similar to the Global Fund for AIDS, Tuberculosis and
Malaria, dedicated specifically to the development and
scale-up of diagnostics and other interventions that safely
reduce human antimicrobial consumption. This analysis
suggests that investment of these resources in CRP testing
in the current context could be cost-beneficial, providing
adherence to their results is high.
The vast proportion of antibiotics dispensed for ARI
through private pharmacies without prescription in Viet
Nam needs to be properly considered [25]. Targeting the
private sector could dramatically increase the impact of
an intervention such as PoC CRP testing on unnecessary
antibiotic use, but has major programmatic challenges.
An obvious solution is to enforce the laws that are in
Fig. 1 Net benefit for CRP testing by unit cost, test adherence, and cost of AMR. The 3 panels indicate the net-benefit of CRP testing in response
to different configurations of the cost of the CRP test, the degree to which health workers adhere with the test results, and the economic cost of
AMR per full course of antibiotic averted. The range of colours reflect the net-benefit of the CRP tests, with dark orange areas indicating instances
where the use of the test is not cost-beneficial, and dark green areas where the test is most-cost-beneficial. With the exclusion of the costs of
AMR ($0), a CRP test would be at best cost-neutral if it was low cost. With the inclusion of the costs of AMR, using either the baseline estimate of
$4.1 or a higher estimate of $14, CRP testing would be cost-benficial even if the cost of the test was as high as $3, providing adherence with test
results was high
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place since 2006 prohibiting unregulated antibiotic sales,
driving these patients to primary and community-care
centres where they can be examined and tested. How-
ever, as indicated by the trial findings and this
cost-benefit analysis, high adherence to the test is critical
to ensuring their impact and cost-effectiveness. To
achieve this, the introduction of CRP tests could be inte-
grated into a broader public health campaign that in-
cludes training and education for both healthcare
workers and patients, to maximize the benefits of both
interventions and achieve a behavioural shift away from
widespread use of antibiotics for minor complaints [26].
Strengths and limitations
This analysis benefitted from detailed primary costing
data from a large clinical trial in Viet Nam evaluating an
intervention to address the urgent need for safe reduc-
tions in antibiotic prescribing in primary care. To our
knowledge these are the only such data from an LMIC
setting. Use of the economic costs of AMR averted in a
cost-benefit analysis of the intervention also represents
an advancement in our ability to perform economic
evaluations of such interventions.
The study has numerous limitations. The primary
measure of effectiveness in the trial was the proportion
of antibiotic prescriptions averted but approximately one
third of patients that were not prescribed an antibiotic
went on to obtain them elsewhere. If the intervention
were to be rolled out in routine care, this should be sup-
plemented by further training and education for health-
care workers and patients to ensure better adherence to
the test. Such programmes will incur higher costs, which
were not accounted for in the analysis. The sensitivity
analysis carried out here indicates that investment in
such education and training programmes for patients
and healthcare workers to improve adherence to CRP
test results could itself be cost-effective.
The CRP test used in the trial relied on a quantitative
reader, requiring some degree of technical experience,
with a relatively high cost per test, whereas in the model
we assume that lower cost lateral flow devices are used in-
stead. It is possible that such devices would have a differ-
ent impact on prescribing than that observed in the trial.
The methods used to quantify the costs of AMR averted
due to reductions in prescribing have numerous limita-
tions detailed in the paper describing their estimation [9].
In addition to these limitations, the adaptation of the costs
of AMR calculated in the Thai setting to the Viet Nam
context also assumed that Viet Nam and Thailand have
similar epidemiological profiles for the prevalence of re-
sistant infections which may not be the case.
As well as guiding whether or not to prescribe an anti-
biotic, CRP testing might also influence prescribing in
terms of choice of antibiotic and duration of treatment,
with implications for costs, health outcomes and AMR.
As there was no evidence of this occurring in the trial
this was not incorporated in the analysis.
Beyond the impact on AMR are other possible costs
and health implications associated with CRP testing that
were not accounted for. Adverse reactions occur in a
small proportion of antibiotic courses, but the frequency
of antibiotic use makes them account for approximately
a quarter of all adverse events recorded in the hospital set-
ting [27, 28]; a study of adverse drug reactions in emer-
gency department visits found antibiotics to be implicated
in a fifth of cases [29]. Second, while over-treatment is a
challenge in all income settings, in many LMICs
under-treatment of respiratory infection in patients with
restricted access to antibiotics imposes a huge morbidity
and mortality toll [30, 31]. In such settings CRP testing
could therefore have a direct beneficial impact on health
outcomes, through identification of patients that require
antibiotic therapy and may not otherwise be detected [32].
Conclusion
Use of CRP test in the context of primary care in LMICs
is likely to incur a modest incremental cost, but this can
be offset by the economic costs of AMR averted, provid-
ing adherence to their results is high. Whether patients
or health providers in LMICs can and should shoulder the
tangible costs is contestable; this study suggests that inter-
national donor support for these purposes is economically
warranted. With low cost tests available and validated,
large scale implementation of CRP point of care tests is
feasible. Implementation of CRP testing on national scales
will pave the way for novel and better systems that are
currently cost-prohibitive once these are better validated
and available at affordable price ranges.
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Additional file 1: Primary costing data from a clinical trial of CRP
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